Life Extension Skin Care Sale

Life Extension Magazine

LE Magazine October 2001

image

Page 4 of 4

References

Allen KL et al. Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia. 1995. J Neurochem 64: 2222-2229.

Ankarcrona M et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. 1995. Neuron 15: 961-973.

Barbiroli B et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. 1997. Cell Molec Biol 43: 741-749.

Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. 1995. Ann Neurol 38: 357-366.

Beal MF et al. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. 1994. Ann Neurol 36: 882-888.

Beal MF et al. Coenzyme Q10 atenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. 1998. Brain Res 783: 109-114.

Bendahan D et al. P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. 1992. Neurology 42: 1203-1208.

Bolanos JP et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. 1997. J Neurochem 68: 2227-2240.

Bonilla E et al. Mitochondrial involvement in Alzheimer’s disease. 1999. Biochim Biophys Acta 1410: 171-182.

Bozner P et al. The amyloid b protein induces oxidative damage of mitochondrial DNA. 1997. J Neuropathol Exp Neurol 56: 1356-1362.

Bresolin N et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. 1990. J Neurol Sci 100: 70-78.

Brookes PS et al. Peroxynitrite and brain mitochondria: evidence for increased proton leak. 1998. J Neurochem 70: 2195-2202.

Brown AM et al. Correlation of the clinical severity of Alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA). 2001. J Mol Neurosci 16: 41-8.

Cassarino DS et al. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. 1999. Brain Res Rev 29: 1-25.

Ebadi M et al. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson’s disease. 2001. Biol Signals Recept 10: 224-53.

Favit A et al. Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration. 1992. J Cereb Blood Flow Metab 12: 638-645.

Fiskum G et al. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. 1999. J Cereb Blood Flow Metab 19: 351-369.

Floyd RA. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen species and nitrogen species as major factors involved in neurodegenerative disease development. 1999. Free Radic Biol Med 26: 1346-1355.

Folkers K et al. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. 1995. Biochim Biophys Acta 1271: 281-286.

Gabuzda D et al. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. 1994. J Biol Chem 269: 13623-13628.

Grieb P et al. Oral coenzyme Q10 administration prevents the development of ischemic brain lesions in a rabbit model of symptomatic vasospasm. 1997. Acta Neuropathol 94: 363-368.

Harman D. A hypothesis on the pathogenesis of Alzheimer’s disease. 1996. Ann NY Acad Sci 786: 152-168.

Koroshetz WJ et al. Energy metabolism defects in Huntington’s disease and effects of Coenzyme Q10. 1997. Ann Neurol 41: 160-165.

Kuroda S et al. Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. 1997. Clin Neurosci 4: 199-212.

Leist M et al. Apoptosis, excitotoxicity, and neuropathology. 1998. Exp Cell Res 239: 183-201.

Lodi R et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. 2001. Ann Neurol 49: 590-6.

Lonnrot K et al. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. 1998. Brit J Pharmacol 124: 1500-1506.

Love S. Oxidative stress in brain ischemia. 1999. Brain Pathol 9: 119-131.

Mariani C et al. Muscle biopsy in Alzheimer’s disease: morphological and biochemical findings. 1991. Clin Neuropathol 10: 171-176.

Mark RJ et al. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid b-peptide. 1997. J Neurochem 68: 255-264.

Mark RJ et al. Amyloid b-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. 1997. J Neurosci 17: 1046-1054.

Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. 1997. Free Radic Biol Med 23: 134-147.

Markesbery WR. Oxidative alterations in Alzheimer’s disease. 1999. Brain Pathol 9: 133-146.

Matsumoto S et a. Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. 1999. J Cereb Blood Flow Metab 19: 736-741.

Matthews RT et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. 1998. Proc Natl Acad Sci USA 95: 8892-8897.

Mazzio E et al. Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells. 2001. Neurotoxicology 22: 283-8.

Mecocci P et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. 1993. Ann Neurol 34: 609-616.

Mizuno Y et al. Mitochondrial dysfunction in Parkinson’s disease. 1998. Ann Neurol 44, Suppl 1: S99-S109.

Mordente A et al. Free radical production by activated haem proteins: protective effect of coenzyme Q. 1994. Molec Aspects Med. 15, Suppl: S109-S115.

Munch G et al. Alzheimer’s disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. 1998. J Neural Transm 105: 439-461.

Murphy AN et al. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. 1999. J Cereb Blood Flow Metab 19: 231-245.

Musumeci O et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. 2001. Neurology 56: 849-55.

Nicotera P et al. Neuronal cell death: a demise with different shapes. 1999. Trends Pharmacol Sci 20: 46-51.

Novelli A et al. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. 1988. Brain Res 451: 205-212.

Ogawa N et al. Survival effect of coenzyme Q10 and naloxone on experimental stroke gerbils. 1986. Pharmacol Biochem Behav 24: 315-317.

Ristow M et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. 2000. Proc Natl Acad Sci U S A. 97: 12239-43.

Sharman EH et al. Effects of age and dietary antioxidants on cerebral electron transport chain activity. 2001. Neurobiol Aging 22: 629-34.

Shults CW et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. 1997. Ann Neurol 42: 261-264.

Shults CW et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzymeQ10 in parkinsonian patients. 1998. Neurology 50: 793-5.

Schulz JB et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. 1996. Neuroscience 71: 1043-1048.

Smith MA et al. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. 1997. J Neurosci 17: 2653-2657.

Sobreira C et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. 1997. Neurology 48: 1238-1243.

Tatton WG et al. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? 1998. Ann Neurol 44, Suppl 1: S134-S141.

Tatton WG et al. Apoptosis in neurodegenerative diseases: the role of mitochondria. 1999. Biochim Biophys Acta 1410: 195-213.

Turner C et al. Mitochondrial dysfunction in neurodegenerative disorders and ageing. 2001. Adv Exp Med Biol 487: 229-51.

Veitch K et al. Global ischemia induces a biphasic response of the mitochondrial respiratory chain. 1992. Biochem J 281: 709-715.

Volpe M et al. Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin. 2000. J Cardiovasc Pharmacol 35, Suppl 2: S45-48.

Webster MT et al. The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. 1998. J Neural Transm 105: 839-853.

Weyer G et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. 1997. Neuropsychobiology 36: 73-82.

Ying W. Deleterious network: a testable pathogenetic concept of Alzheimer’s disease. 1997. Gerontology 43: 242-253.

Zeng Z et al. Mitochondrial DNA deletions are associated with ischemia and aging in Balb/c mouse brain. 1999. J Cell Biochem 73: 545-553.



Back to the Magazine Forum